ss-lup-332 peptide FAQ

Stacking SS-LUP-332 peptide with NAD+ precursors (nicotinamide riboside, NMN) may produce additive effects since they target different steps in mitochondrial metabolism. NAD+ precursors support electron carrier availability while SS-LUP-332 peptide improves electron transport efficiency. Combining it with AMPK activators like AICAR introduces redundancy, as both compounds ultimately increase oxidative phosphorylation. Avoid combining with uncoupling agents (DNP, 2,4-dinitrophenol). The mechanisms oppose each other and create unpredictable metabolic stress.

Use it without concern. SLU PP332 same as SS-LUP-332 represents the same molecular structure regardless of supplier labelling. Verify purity via HPLC or request a certificate of analysis showing >98% purity and correct molecular weight (typically supplied by reputable peptide manufacturers). The naming variation exists in catalogues and publications, not in the peptide itself. Our team cross-references both designations when sourcing to ensure we're ordering the intended compound. Dual nomenclature is standard for experimental peptides originating from academic labs before formal pharmaceutical naming conventions are applied.

Discard it. Cloudiness indicates peptide aggregation caused by improper reconstitution, temperature excursion, or degradation over time. Aggregated peptides lose mitochondrial targeting capability and may trigger immune responses if administered. SLU PP332 same as SS-LUP-332 should dissolve into a clear, colourless solution within 5–10 minutes of adding bacteriostatic water. If cloudiness appears immediately, the lyophilised powder was contaminated or improperly stored before shipping. If it develops after days in refrigeration, oxidative degradation has occurred. This peptide's stability window is shorter than most, requiring fresh reconstitution every 2–3 weeks maximum.

Verify dosing accuracy first. The published effective range is 5–10mg/kg subcutaneously in rodents, and underdosing is the most common protocol error. Mitochondrial effects are dose-dependent and tissue-specific; if your model uses tissues with low oxidative capacity (white adipose, fast-twitch glycolytic muscle), uptake will be minimal. Consider switching to oxidative muscle groups (soleus, heart) or extending the treatment window beyond 14 days. Mitochondrial remodelling requires sustained exposure.

SS-LUP-332 peptide is supplied as lyophilised powder and must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 21 days. The mitochondrial-targeting sequence contains hydrophobic residues that aggregate at room temperature, rendering the compound inactive. Any temperature excursion above 8°C for more than 4 hours likely denatures the structure. If reconstituted solution appears cloudy or contains visible particulate, discard it. Aggregated peptide will not cross mitochondrial membranes.

Cease administration immediately and monitor core temperature every 15 minutes until it returns to baseline. SLU PP332's mitochondrial uncoupling effect dissipates within 6–8 hours due to its short half-life, but accumulated heat takes longer to clear if ambient temperature is warm or physical activity elevated metabolic rate further. Rodent studies showed temperature elevations plateau at 1.2–1.8°C above baseline at effective doses, but individual variation exists. Any rise exceeding 2°C suggests overdosing or hypersensitivity. Discontinue the protocol entirely and reassess dosing from a lower starting point if reintroducing the compound.

Ship lyophilized peptide on dry ice in insulated packaging with temperature monitoring. Never ship reconstituted peptide unless absolutely unavoidable. Lyophilized SS-LUP-332 tolerates shipping at -20°C for 48–72 hours without degradation, but once reconstituted, the peptide must remain at 2–8°C continuously, which standard cold packs cannot reliably maintain beyond 24 hours. If you must ship reconstituted peptide, use a validated pharmaceutical shipper with real-time temperature logging and next-day delivery. Any excursion above 8°C compromises peptide integrity, and there's no visual indicator to confirm whether denaturation occurred.

Verify three variables before concluding the peptide is inactive: dosage accuracy, administration timing, and exercise protocol intensity. The Saint Louis University studies that established SS-LUP-332's 70% endurance improvement used standardized treadmill protocols at 60–70% VO2max. Running to exhaustion at moderate intensity, not maximal sprints. If your protocol uses high-intensity interval training or maximal effort testing, the metabolic pathway being tested differs fundamentally, and SS-LUP-332's effects may not manifest the same way. Additionally, confirm your reconstitution followed proper bacteriostatic water ratios and that the peptide was stored refrigerated immediately after mixing.

Subcutaneous administration is viable but requires dose adjustment and monitoring for injection-site reactions. Published SS-LUP-332 research used intraperitoneal injection because it provides rapid systemic distribution with minimal tissue irritation, but subcutaneous delivery. Common in clinical settings. Can achieve similar plasma concentrations if dose timing accounts for slower absorption kinetics. Expect a 20–30 minute delay to peak plasma concentration compared to intraperitoneal administration, and monitor injection sites for redness, swelling, or nodule formation, which occasionally occur with concentrated peptide solutions. If injection-site reactions appear, dilute the peptide further or switch to intraperitoneal delivery.

Do not use it. Contact the supplier immediately. SS-LUP-332 is synthesized and shipped as lyophilized powder specifically because peptides in liquid form degrade rapidly without specialized stabilizers, and even with stabilizers, pre-mixed peptides have significantly shorter shelf lives than lyophilized forms. A clear liquid peptide arriving without your explicit order of a pre-mixed format suggests either a shipping error, contamination during packaging, or exposure to heat that caused premature reconstitution. Real Peptides ships SS-LUP-332 as sterile lyophilized powder in sealed vials under cold-chain conditions to ensure the peptide reaches your lab in its most stable form.